On June 23, 2021, the results of the fifth batch of national centralized drug procurement were released. The Sinokase hydrochloride tablet (trademark name: Ruianto®) independently developed by Fujian Haixi New Drug Creation Co., Ltd. won the bid at the highest price. Seven supply provinces (regions) include Hebei, Inner Mongolia, Shanghai, Shandong, Guizhou, Yunnan and Gansu.
Ryanto® Sinacasai hydrochloride tablets are used to treat secondary hyperparathyroidism (SHPT) in patients with chronic nephropathy (CKD) maintenance dialysis and elevated calcium levels (high calcium blood) in patients with parathyroid cancer. Both Sinacasai hydrochloride tablets are a significant medical progress and the first such drug to benefit patients with kidney and parathyroid disease since the discovery of calcium-like compounds in the early 1990s. At the same time, the KDIGO guide and the domestic authoritative guide recommend Sinacaser as a SHPT first-line drug, which has an extremely significant clinical effect.
The winning bid for the centralized procurement of drugs is the company's second national drug collection after Ambili® Moxabride Citrate Tablets. This will further enrich the company's listed drug pipeline, enhance the company's brand influence, and have a positive impact on the company's future business performance.
